Logo image of EURK

EUREKA ACQUISITION CORP (EURK) Stock Fundamental Analysis

NASDAQ:EURK - Nasdaq - KYG321681093 - Common Stock - Currency: USD

10.27  +0.02 (+0.2%)

Fundamental Rating

2

EURK gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 0 industry peers in the Unkown industry. EURK scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. EURK is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year EURK was profitable.
In the past year EURK has reported a negative cash flow from operations.
EURK Yearly Net Income VS EBIT VS OCF VS FCFEURK Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2023 2024 0 200K -200K

1.2 Ratios

Industry RankSector Rank
ROA 1.44%
ROE 1.44%
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
EURK Yearly ROA, ROE, ROICEURK Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2023 2024 0 -5 -10 -15 -20 -25

1.3 Margins

EURK does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
EURK Yearly Profit, Operating, Gross MarginsEURK Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2023 2024

More info and screens

6

2. Health

2.1 Basic Checks

EURK has more shares outstanding than it did 1 year ago.
EURK has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
EURK Yearly Shares OutstandingEURK Yearly Shares OutstandingYearly Shares Outstanding 2023 2024 2M 4M 6M
EURK Yearly Total Debt VS Total AssetsEURK Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2023 2024 10M 20M 30M 40M 50M

2.2 Solvency

An Altman-Z score of 819.82 indicates that EURK is not in any danger for bankruptcy at the moment.
EURK has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 819.82
ROIC/WACCN/A
WACCN/A
EURK Yearly LT Debt VS Equity VS FCFEURK Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2023 2024 0 10M 20M 30M 40M 50M

2.3 Liquidity

A Current Ratio of 10.26 indicates that EURK has no problem at all paying its short term obligations.
EURK has a Quick Ratio of 10.26. This indicates that EURK is financially healthy and has no problem in meeting its short term obligations.
Industry RankSector Rank
Current Ratio 10.26
Quick Ratio 10.26
EURK Yearly Current Assets VS Current LiabilitesEURK Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2023 2024 200K 400K 600K

More info and screens

1

3. Growth

3.1 Past

EURK shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 4287.50%, which is quite impressive.
EPS 1Y (TTM)4287.5%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%934.12%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EURK Yearly Revenue VS EstimatesEURK Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2023 2024
EURK Yearly EPS VS EstimatesEURK Yearly EPS VS EstimatesYearly EPS VS Estimates 2023 2024

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

Based on the Price/Earnings ratio of 93.36, the valuation of EURK can be described as expensive.
Compared to an average S&P500 Price/Earnings ratio of 29.35, EURK is valued quite expensively.
Industry RankSector Rank
PE 93.36
Fwd PE N/A
EURK Price Earnings VS Forward Price EarningsEURK Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
EURK Per share dataEURK EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 4 6

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

No dividends for EURK!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

EUREKA ACQUISITION CORP

NASDAQ:EURK (3/7/2025, 8:22:28 PM)

10.27

+0.02 (+0.2%)

Chartmill FA Rating
GICS SectorN/A
GICS IndustryGroupN/A
GICS IndustryN/A
Earnings (Last)N/A N/A
Earnings (Next)N/A N/A
Inst Owners66.78%
Inst Owner Change-8.76%
Ins Owners6.74%
Ins Owner Change0%
Market Cap78.57M
AnalystsN/A
Price TargetN/A
Short Float %0%
Short Ratio0
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE 93.36
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 1.32
P/tB 1.32
EV/EBITDA N/A
EPS(TTM)0.11
EY1.07%
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)-0.04
FCFYN/A
OCF(TTM)-0.04
OCFYN/A
SpS0
BVpS7.76
TBVpS7.76
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA 1.44%
ROE 1.44%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score6
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 10.26
Quick Ratio 10.26
Altman-Z 819.82
F-Score6
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)4287.5%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%934.12%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-6581.13%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-6469.77%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-6469.77%
OCF growth 3YN/A
OCF growth 5YN/A